Hemophagocytic Lymphohistiocytosis Secondary to Immune Checkpoint Inhibitor Therapy

Hemophagocytic lymphohistiocytosis (HLH) is a fatal systemic inflammatory syndrome. HLH has been reported as a rare immune-related adverse event (irAE) in patients receiving immunotherapy with nivolumab, ipilimumab, and/or pembrolizumab. The data are limited to case reports and case series. The obje...

Descripción completa

Detalles Bibliográficos
Autores principales: Rajapakse, Pramuditha, Andanamala, Haripriya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9076146/
https://www.ncbi.nlm.nih.gov/pubmed/35571340
http://dx.doi.org/10.14740/wjon1464

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9076146/
https://www.ncbi.nlm.nih.gov/pubmed/35571340
http://dx.doi.org/10.14740/wjon1464

Ejemplares similares